Archive - Latest News Search Engine - Global and Local Breaking News

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

Middle East tensions: Are Indians being forced to leave Israel? What embassy said

Middle East tensions: Are Indians being forced to leave Israel? What embassy said

I shop for a living and these are the wrinkle-resistant dresses I'm grabbing for summer travels

I shop for a living and these are the wrinkle-resistant dresses I'm grabbing for summer travels

GMS Inc. price target raised to $95 from $71 at Barclays

GMS Inc. price target raised to $95 from $71 at Barclays

Your briefing

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinez...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

Middle East tensions: Are Indians being forced to leave Israel? What embassy said

Amidst rising Middle East tensions, the Indian embassy in Israel refuted claims of forcing Indian citizens to leave, dismissing a fake social media po...

Middle East tensions: Are Indians being forced to leave Israel? What embassy said

I shop for a living and these are the wrinkle-resistant dresses I'm grabbing for summer travels

I shop for a living and these are the wrinkle-resistant dresses I'm grabbing for summer travels

GMS Inc. price target raised to $95 from $71 at Barclays

GMS Inc. price target raised to $95 from $71 at Barclays